oa Pharmacological management of psychiatric agitation in COVID-19 hospitalized patients

References

1. Wong AH, Roppolo LP, Chang BP, Yonkers KA, Wilson MP, Powsner S, et al. Management of agitation during the COVID-19 pandemic. West J Emerg Med. 2020;
   [Google الباحث العلمي]
2. Garg RK, Paliwal VK, Gupta A. Encephalopathy in patients with COVID-19: A review. Journal of Medical Virology. 2021.
   [Google الباحث العلمي]
3. Kashani KB. Hypoxia in COVID-19: Sign of Severity or Cause for Poor Outcomes. Mayo Clinic Proceedings. 2020.
   [Google الباحث العلمي]
4. Martinotti G, Barlati S, Prestia D, Palumbo C, Giordani M, Cuomo A, et al. Psychomotor agitation and hyperactive delirium in COVID-19 patients treated with aripiprazole 9.75 mg/1.3 ml immediate release. Psychopharmacology. 2020.
   [Google الباحث العلمي]
5. Ostuzzi G, Gastaldon C, Papola D, Fagiolini A, Dursun S, Taylor D, et al. Pharmacological treatment of hyperactive delirium in people with COVID-19: rethinking conventional approaches. Ther Adv Psychopharmacol. 2020;
   [Google الباحث العلمي]
6. Yoon HJ, Park KM, Choi WJ, Choi SH, Park JY, Kim JJ, et al. Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. BMC Psychiatry. 2013;
   [Google الباحث العلمي]
7. Ojeahere MI, de Filippis R, Ransing R, Karaliuniene R, Ullah I, Bytyçi DG, et al. Management of psychiatric conditions and delirium during the COVID-19 pandemic across continents: lessons learned and recommendations. Brain, Behav Immun - Heal. 2020;
   [Google الباحث العلمي]
8. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clinic Proceedings. 2006.
   [Google الباحث العلمي]